SBIR/STTR Research Award
AN EXPANDED GENETIC INFORMATION SYSTEM
Award amount
$500,000Program and phase
STTR · Phase IIAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ERAGEN BIOSCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The DNA alphabet is not limited to the
four standard nucleotides. Rather, twelve nucleobases forming six base pairs
joined by mutually exclusive hydrogen bonding patterns are possible within the
geometry of the Watson-Crick base pair. These form An Expanded Genetic
Information System (Aegis), a new, "rule based" molecular recognition system
that carries protein functionality, can be prepared in combinatorial form, and
can be copied much like nucleic acids. Given the rich understanding of this
system after a decade of research in the Benner laboratory, Aegis is a
technology transfer opportunity. In the Phase I study, a comprehensive set of
experiments validated the ability of Aegis to provide a set of orthogonal,
non-cross reacting tags useful to support highly multiplexed (100 or more
analytes) DNA diagnostics systems. These included studies in both solution and
solid phase, with the Luminex instruments that support multiplexing, and with
polymerases. In Phase II, we will prepare 1000 independently binding DNA-like
tags, further develop tools to support genotyping of individual patients, and
select for polymerases that incorporate both functionalized nucleotides and
Aegis components into oligonucleotides.
PROPOSED COMMERCIAL APPLICATION:
Chemical systems that support "rule based molecular recognition" have wide commercial applicability, including in come "blue skies" (nanotechnology and molecular computing, for example). More immediately, the Aegis system here is supporting a commercial diagnostics system, and has led in the Phase I period to an assay that detects single nucleotide polymorphisms (SNPs). Such assays promise a revolution in predictive medicine and personalized care, with potential market value.
Technology keywords
Not reported